ProBioGen AG’s Post

Kapoose Creek Bio is thrilled to announce that the company has entered into a global exclusive technology licensing agreement with Adapsyn Bioscience, creating a combined world-leading technology platform that harnesses AI to address the most persistent barriers in natural product drug discovery.   In addition to the company’s informatics technologies, Kapoose Creek Bio is acquiring Adapsyn Bioscience’s extensive natural products collections, its chemistry laboratory housed in McMaster Innovation Park, and an outstanding team of four scientists, whose expertise spans chemistry, microbiology and computation.    This strategic agreement with Adapsyn Bioscience will accelerate Kapoose Creek Bio’s drug development pipeline, which already includes two lead compounds with indications encompassing neurodegeneration and neuropsychiatric diseases, and future R&D efforts.    Read our release here: https://lnkd.in/gqgHT37W   #drugdiscovery #AI #biopharma #biotechpartnerships #biotechinnovation #lifesciences #biotechdeals #neurodegeneration

BIT Mesra’s Department of Bioengineering and Biotechnology is gearing up to organize the International Conference on Emerging Trends in Translational Bioinformatics (ET2B) to be held from 5-7 December 2024. To mark this celebration, a Curtain Raiser Meet the Press event was conducted today. Catch glimpses from the Press Conference held. The Goal of the #Conference is to unite Global Leaders in #Bioinformatics and Clinical Practice.  #meetthepress #Biotechnology #BITMesra #internationalconference #globalleaders #PressConference

🇩🇪 🏴󠁧󠁢󠁳󠁣󠁴󠁿INTERNATIONAL CONFERENCE🇩🇪 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Still time to register for the 2nd Scotland - Rheinland-Pfalz Life Sci and Biotech Conference on May 14th (online) Co-hosted by RPTU Kaiserslautern We will have a plenary talk from BASF, a panel discussion on funding and scientific presentations on the following topics: - Sustainability in Biotechnology - Neurodegeneration and Healthy Ageing - Biotechnology for Advanced Therapies - Engineering Biology - AI and Data in Healthcare https://buff.ly/47U4xd6

🎉 #portfolioupdate 🎉 Our latest portfolio company is Tamarind Bio, based in San Francisco. Founded in November 2023 by by Deniz Kavi & Sherry Liu who met at Stanford, Tamarind Bio is revolutionizing drug discovery possibilities in the biotech industry. Their innovative platform offers no-code, user-friendly computational biology tools for drug discovery, focusing on protein design, molecular docking, and structure prediction. These tools require no initial setup, enabling scientists to accelerate their research effortlessly. Tamarind Bio was selected for the Winter 24 cohort of Y Combinator. With over a thousand freemium pilot users from top-tier academic institutions worldwide - including Oxford, Stanford, Berkeley, MIT, and the University of Cambridge - Tamarind Bio is poised to transform the drug development landscape. The most recent inbound paid users from the National Institute of Health provide another solid endorsement of Tamarind Bio's growing reputation as a truly remarkable tool for researchers. Learn more about our latest addition to our portfolio: https://www.tamarind.bio/ #venturecapital #vcfund #tamarindbio #treeoVC #biotech #bioinformatics 

Deck out for the International Conference on Emerging Trends in Translational Bioinformatics to be held from 5-7 December 2024, organized by the Department of Bioengineering and Biotechnology at BIT Mesra. The Goal of the #Conference is to unite Global Leaders in #Bioinformatics and Clinical Practice.  #ChiefGuest #Biotechnology #BITMesra #internationalconference #globalleaders #countdown

Humbled and excited to share my journey with the Cavidi team! Though my expertise isn't in biochemistry, collaborating closely with our leading biochemists on the fundamentals of biology has been an enlightening experience. What's truly remarkable is witnessing the rapid adoption of our new BOLD technology. This innovation isn't confined to just fundamental research; it's making significant strides in practical applications as well. A standout example of this progress is Exazym. This add-on reagent tool is not just another advancement; it's revolutionizing the way we approach immunodiagnostics. By enhancing the sensitivity of any ELISA, (over 50 fold) Exazym is setting a new standard in the field. It's inspiring to see how BOLD technology is paving the way for breakthroughs that were once thought to be years away. The future of biochemistry and diagnostics looks incredibly bright, thanks to these innovations. #Biochemistry #Innovation #BOLDtechnology #Cavidi #Exazym #Immunodiagnostics

MULTIOMICS: Integrative Approaches to Biological Research| TRENDS & CAREER SCOPE | #bioinformatics #biotech #biotechnology #multiomics #omics #drjyotibala #molelixirinformatics #genomics #programming #proteomics #biology https://lnkd.in/gRZGud35

𝗪𝗲 𝗮𝗿𝗲 𝗵𝗼𝗻𝗼𝗿𝗲𝗱 𝘁𝗼 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲 𝗗𝗿. 𝗬𝘃𝗲𝘀 𝗕𝗿𝗶𝗲𝗿𝘀, Associate Professor and head of the Laboratory of Applied Biotechnology at Ghent University (Belgium), as one of the esteemed speakers at the upcoming BioGENext conference! With a wealth of expertise in biotechnology, Dr. Briers and his group leads cutting-edge research at Ghent University, focusing on on the synthetic biology of modular proteins with a particular focus of phage lysins, phage receptor-binding proteins, engineered phages and carbohydrate-active enzymes, spanning basic to translational research. He co-founded the Belgian Society for Viruses of Microbiology in 2022 and currently serves as its chair. Furthermore, he is the CEO of Obulytix, a spinoff company focused on developing phage lysins as antibiotics, which he co-founded in 2023. ➡️𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝘁𝗼 𝗵𝗲𝗮𝗿 𝗳𝗿𝗼𝗺 𝗗𝗿. 𝗕𝗿𝗶𝗲𝗿𝘀 𝗮𝗻𝗱 𝗼𝘁𝗵𝗲𝗿 𝗲𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀 𝗮𝗻𝗱 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝘁 𝘁𝗵𝗲 𝗕𝗶𝗼𝗚𝗘𝗡𝗲𝘅𝘁 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲: https://lnkd.in/dRMKAMWX Follow us on social media using the hashtags #BioGENext #BioGENext2024 #BiogenextConference #ScientificConference #Research #Biotech #Ukraine #biotherapeutics #mRNA #GenEditing #bioinformatics #biomarkers #BiomedicalResearch #Innovation #Collaboration #Science #TherapyDevelopment #Сonference #Biotherapy #Abstractsubmission #Research #Conference #GenomeEditing #GeneticTherapies #ConferenceSpeaker #CRISPR #MedicalResearch #SyntheticBiology #PhageTherapy

🔬 Just wrapped up my online presentation on "Introduction to Cell Culture" via Telegram! 🎓 It was an engaging session where I delved into the fundamentals of cell culture and its significance in research and innovation. 💡 From basic techniques to diverse applications in fields like medicine and biotechnology, we explored it all! 🌱 If anyone is interested in the presentation material, feel free to reach out, and I'll be happy to share it with you! #CellCulture #Research #Biotechnology #Medicine #ScienceEducation

*** Paper alert *** Aviv Regev and her team from Genentech published a paper today in Nature. https://lnkd.in/dMNYF5k5 The paper describes the tool SCimilarity, a metric learning framework to learn a unified and interpretable representation that enables rapid queries of tens of millions of cell profiles from diverse studies for cells that are transcriptionally similar to an input cell profile or state. Myllia Biotechnology CSO Tilmann Burckstummer anticipates that this model will become useful to compare transcriptional profiles of different cell types and cell states: "At Myllia, we perform single-cell CRISPR screens at scale. We are often confronted with the problem that Dr. Regev has tackled here. Having framework for quantitative comparison of different cell populations will greatly facilitate the computational analysis of the large datasets we produce." www.myllia.com #mylliabio #singlecells #crisprcas9